{br} STUCK with your assignment? {br} When is it due? {br} Get FREE assistance. Page Title: {title}{br} Page URL: {url}
UK: +44 748 007-0908, USA: +1 917 810-5386 [email protected]
  1. Dayvigo Sleeping medication    

     

    QUESTION

    Discuss indications for use, FDA approval, major interactions, side effects, contraindications, and so on
    Make bullets o slides and notes in speakers notes 

 

Subject Nursing Pages 3 Style APA

Answer

Dayvigo: Sleeping Medication

  • This presentation discussed Dayvigo (lemborexant) indications for use, U.S. Food and Drug Administration approval, major interactions, side effects, and contraindications.

Indications for Use

  • Dayvigo (lemborexant) is an orexin receptor antagonist whose controlled substance schedule is pending (FDA, 2019).
  • Dayvigo is indicated for the treatment of adults with trouble falling or staying asleep (insomnia) (U.S. Food and Drug Administration (FDA), 2020).
  • It is found as an oral tablet (5 mg and 10 mg tablets). It is taken not more than once per night; it should be taken straightaway after going to bed (FDA, 2019; 2020).
  • Insomnia patients who take the drug tend to fall asleep faster and stay asleep longer compared to patients who receive placebo (FDA, 2020).
  • The drug is being investigated for management of irregular sleep-wake rhythm disorder associated with mild to moderate Alzheimer’s disease (Scott, 2020).

FDA Approval

  • Dayvigo received its first approval in December 2019 in the United States (Scott, 2020).
  • FDA approved Dayvigo for management of insomnia based on primary evidence derived from two clinical trials (Trial 2/NCT02783729 and Trial 1/NCT02952820), which involved a total of 1,692 patients (FDA, 2020).
  • The trials were conducted in 164 sites in Canada, United States, Europe, Japan, Mexico, Taiwan, and Korea (FDA, 2020).
  • Mechanism of action is by blocking the binding of neuropeptides orexin B and orexin A to OX2R and OXIR, this mechanism is thought to suppress the wake drive (FDA, 2019).

Major Interactions

  • Concomitant use with moderate (verapamil and fluconazole) or strong (clarithromycin and itraconazole) CYP3A inhibitors should be avoided (Ardeljan & Hurezeanu, 2020; FDA, 2019).
  • CYP3A inhibitors may increase the side effects of Dayvigo.
  • The maximum dose of the drug when co-administered with weak CYP3A inhibitors is 5 mg (Ardeljan & Hurezeanu, 2020; FDA, 2019).
  • Concomitant use with strong CYP3A inducers (carbamazepine, rifampin, and St. John’s wort) or moderate CYP3A inducers (efavirenz, bosentan, modefinil, and etravirine) should be avoided (Ardeljan & Hurezeanu, 2020; FDA, 2019).

Side Effects

Dayvigo may cause a number of side effects including:

  • Drowsiness, which is the most common side effect (FDA, 2020).
  • Impaired ability to operate machinery and decreased daytime alertness (FDA, 2020).
  • Sleep paralysis (this is temporary inability to talk or walk while waking up or while going to sleep) (FDA, 2020).
  • Complex sleep behaviors including sleep-driving and sleep-walking.
  • Hallucinations, which occur while waking up or going to sleep (FDA, 2020).
  • Suicidal thoughts and worsening depression (FDA, 2020).
  • Compromised respiratory function (FDA, 2019).

Contraindications

  • Dayvigo is contraindicated in patients with narcolepsy (FDA, 2019).

References

 

Related Samples

WeCreativez WhatsApp Support
Our customer support team is here to answer your questions. Ask us anything!
👋 Hi, how can I help?